EAST ST. LOUIS, Ill. - Boehringer Ingelheim International GmbH (BII) will face sanctions, possibly including adverse inference and the loss of certain affirmative defenses, after the Pradaxa maker said it cannot produce the complete files of a former high-level scientist involved in the development of the blood thinner, the judge presiding over a multidistrict litigation said in a Dec. 18 order (In Re: Pradaxa $(Dabigatran Etexilate$) Products Liability Litigation, MDL Docket No. 2385, No. 2:13-md-2385, S.D. Ill.; 2013 U.S. Dist. LEXIS 177597).